RESISTANCE TO BETA-LACTAMS IN MYCOBACTERIUM-FORTUITUM

被引:22
|
作者
FATTORINI, L
OREFICI, G
JIN, SH
SCARDACI, G
AMICOSANTE, G
FRANCESCHINI, N
CHOPRA, I
机构
[1] UNIV LAQUILA,DEPT SCI & BIOMED TECHNOL,INST BIOL CHEM & MOLEC BIOL,I-67100 LAQUILA,ITALY
[2] UNIV BRISTOL,SCH MED SCI,DEPT MICROBIOL,BRISTOL BS8 1TD,AVON,ENGLAND
[3] IST SUPER SANITA,DEPT BIOMETR,I-00161 ROME,ITALY
关键词
D O I
10.1128/AAC.36.5.1068
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
It is widely assumed that the-high level of intrinsic resistance to beta-lactam antibiotics exhibited by mycobacteria results from the combination of factors including permeability to the drugs, beta-lactamase production, and affinity for penicillin-binding proteins (PBPs). We conducted an evaluation of the second and third factors by isolating nitrosoguanidine-induced mutants from the beta-lactamase-producing strain Mycobacterium fortuitum ATCC 19542 that displayed either elevated or reduced resistance to various beta-lactam antibiotics. The mutants studied included D1 (a beta-lactamase producer with high penicillin resistance), gamma-27 (a low-level beta-lactamase producer with low penicillin resistance), and D316 (a high-level beta-lactamase producer with high penicillin resistance). In all strains examined, four major PBPs, named 1, 2a, 2b, and 3, with apparent molecular weights of 102,000, 90,000, 87,000, and 50,000, respectively, were found. The MICs of various beta-lactams toward ATCC 19542 and its mutants were considered in the context of beta-lactamase production, the quantity of PBPs synthesized, and their affinities for beta-lactam antibiotics. The data obtained show that beta-lactamase production is likely to be an important factor in the expression of resistance by clinical isolates and that PBP alterations can contribute to resistance at least in laboratory-derived mutants.
引用
收藏
页码:1068 / 1072
页数:5
相关论文
共 50 条
  • [41] ARTHRITIS OF THE SUBTALAR JOINT DUE TO MYCOBACTERIUM-FORTUITUM
    COLVER, GB
    CHATTOPADHYAY, B
    FRANCIS, RS
    KUNZRU, KMN
    BRITISH MEDICAL JOURNAL, 1981, 283 (6289): : 469 - 470
  • [42] ENZYMATIC AND IMMUNOLOGICAL CHARACTERIZATION OF MYCOBACTERIUM-FORTUITUM COMPLEX
    BINKO, BP
    BARTHOLOMEW, WR
    JOURNAL OF CLINICAL MICROBIOLOGY, 1978, 8 (02) : 246 - 251
  • [43] A FAMILY OF DIACYLTREHALOSES ISOLATED FROM MYCOBACTERIUM-FORTUITUM
    ARIZA, MA
    MARTINLUENGO, F
    VALEROGUILLEN, PL
    MICROBIOLOGY-SGM, 1994, 140 : 1989 - 1994
  • [44] STUDY OF INVITRO SUSCEPTIBILITY OF MYCOBACTERIUM-FORTUITUM TO AMINOGLYCOSIDE AND BETA-LACTAM ANTIBIOTICS
    CASAL, M
    RODRIGUEZ, F
    ANNALES DE MICROBIOLOGIE, 1981, B132 (01): : 51 - 56
  • [45] ISOELECTRIC-FOCUSING OF BETA-LACTAMASES IN MYCOBACTERIUM-FORTUITUM - ASSOCIATION OF A SINGLE ENZYME PATTERN WITH CEFOXITIN RESISTANCE
    WALLACE, RJ
    NASH, DR
    UDOU, T
    STEINGRUBE, VA
    STEELE, LC
    SWENSON, JM
    SILCOX, VA
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1985, 132 (05): : 1093 - 1097
  • [46] OSTEOMYELITIS CAUSED BY MYCOBACTERIUM-FORTUITUM - REPORT OF A CASE
    SLOTNICK, IJ
    SACKS, HJ
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1973, 59 (04) : 574 - 575
  • [47] PLASMID PROFILES OF MYCOBACTERIUM-FORTUITUM COMPLEX ISOLATES
    LABIDI, A
    DAUGUET, C
    GOH, KS
    DAVID, HL
    CURRENT MICROBIOLOGY, 1984, 11 (04) : 235 - 240
  • [48] MYCOBACTERIUM-FORTUITUM PULMONARY INFECTION COMPLICATING ACHALASIA
    HOWARD, RS
    WOODRING, JH
    MACVANDIVIERE, H
    DILLON, ML
    SOUTHERN MEDICAL JOURNAL, 1991, 84 (11) : 1391 - 1393
  • [49] THE 3RD BIOVARIANT OF MYCOBACTERIUM-FORTUITUM
    GRANGE, JM
    TUBERCLE AND LUNG DISEASE, 1993, 74 (05): : 349 - 349
  • [50] THE USE OF CLOFAZIMINE AS TREATMENT FOR MYCOBACTERIUM-FORTUITUM IN A CAT
    MICHAUD, AJ
    FELINE PRACTICE, 1994, 22 (03): : 7 - 9